The objective of this research group is to investigate cardiac disease interlinked with pregnancy or the postpartum period.
Prof. Karen Sliwa, Hatter Institute
Prof. Denise Hilfiker-Kleiner, Hannover University, Germany
Prof. Michael Böhm, University of Saarland, Homburg, Germany
Prof. Sandrine Lecour, Hatter Institute
Dr. Lori Blauwet, Mayo Clinic, Rochester, USA
Dr John Anthony, Dept Obstetrics & Gynaecology, University of Cape Town
Dr. Kemi Tibazarwa, Hatter Institute
Dr Tony Lachmann, Dept Obstetrics & Gynaecology, University of Cape Town
Dr Catherine Elliot, Dept Obstetrics & Gynaecology, University of Cape Town
Dr Friedrich Thienemann, Institute of Infectious Disease & Molecular Medicine, University of Cape Town
The team has for many years investigated the pathogenesis, etiology, epidemiology and management of a condition, peripartum cardiomyopathy (PPCM), common in African women. PPCM is a disease which develops in previously healthy women, before delivery or in the postpartum period, with a reported mortality of about 25%.
This research has resulted in numerous publications in prestigious journals such as the European Heart Journal (2006), Journal of the American College of Cardiology, The Lancet (2006), Cell ( 2007) and Circulation (2011, 2012, 2013). Some aspects of the research forms part of collaborative projects with the University of Hannover, Germany (Prof. Hilfiker-Kleiner) and the University of Saarland, Homburg, Germany (Prof. Böhm).
Our team reported that a ‘broken’ Prolactin (16kd) causes activation of pro-apoptotic signalling pathways in the heart, leading to left ventricular dilatation and a failing heart.
We have investigated the effect of a medication (Bromocryptine) inhibiting prolactin in a randomized study of newly diagnosed patients with PPCM.
The positive results of this proof-of-concept pilot was published in Circulation in March 2010.
Further research has shown that endothelial microparticles (EMPs), vesicles released from endothelial cellular membranes during cell activation/apoptosis, could directly demonstrate endothelial damage in PPCM (Walenta K, Sliwa K, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012; 33: 1469-1479)
It is still unclear whether hypertension in pregnancy-induced heart failure (PIH-HF) and peripartum cardiomyopathy (PPCM) are disparate clinical entities with different underlying pathogenetic mechanisms, natural histories and disease outcomes, which may sometimes overlap.
We have commenced a prospective registry of PIH-HF and PPCM to systematically examine the similarities and differences between PPCM and PIH-HF. Biomarker studies will be used to further investigate the mechanism of disease.
Prof Sliwa’s research translated into the establishment, in 2009, of the Peripartum Cardiomyopathy Working Group, Heart Failure Association of the European Cardiac Society (ESC), chaired by Prof Karen Sliwa, which has subsequently leveraged funding for a 1000 patient international registry on PPCM. The first 100 patients have been recruited.
Karen Sliwa (Cape Town, South Africa)
Burkert Pieske (Graz, AT)
Denise Hilfiker-Kleiner (Hannover, DE)
John McMurray (Glasgow, GB)
Alexandre Mebazaa (Paris,FR)
Mark Petrie (Glasgow, GB)
Vera Regitz-Zagrosek (Berlin, DE)
Maria Schaufelberger (Gothenburg, SE)
Petar Seferovic (Belgrade, RS)
Ajay Shah (London, GB)
Luigi Tavazzi (Cotignola, IT)
Dirk van Veldhuisen (Groningen, NL)
Karin van Spaendonck-Zwart (Amsterdam, NL)
Uri Elkayam (Los Angeles, US)
Frederic Mouquet (Lille, FR)
Katrin Bachelier (Homburg, DE)
Affilate member: Amam Mbakwem (Nigeria)
The rationale for this cohort study is that the incidence of cardiovascular disease during pregnancy is increasing across the world, resulting in significant morbidity and mortality. Etiology and outcome varies between developing and developed countries. In developing countries, women may have pre-existing disease unmasked by pregnancy (e.g. mitral stenosis due to rheumatic heart disease), a superimposed condition unique to pregnancy (e.g. peripartum cardiomyopathy), or a complication of pregnancy itself (e.g. pregnancy-induced hypertension). There is, however, a lack of data from Africa on this important topic.
This cohort study was initiated by Professor Karen Sliwa at the Cardiac Clinic, Department of Medicine, Groote Schuur Hospital, in conjunction with Professor John Anthony, Department of Obstetrics and Gynaecology, Groote Schuur Hospital, in July 2011.
The objective is to study the natural history of these pregnant women with cardiovascular disease, pre- and postpartum, as well as to identify risk factors and clinical predictors of outcome.
Clinicians are invited to refer patients with a known cardiac condition (e.g. operated congenital heart disease, operated valvular disease) or patients with a suspected cardiac condition, during or post pregnancy, to the Cardiac Disease and Maternity Clinic. More than 250 patients from Cape Town have been entered into the cohort so far.
Serum and plasma are stored at the Hatter Institute. Detailed information on clinical presentation, socio-economic factors, laboratory markers, ECG and echocardiography is collected via a web-based data entry platform.
The platform is now being used to expand the cohort to other African sites, e.g. Nigeria (Prof Amam Mbakwam and Dr Dike Ojji) and Kenya (Dr Olaf Forster).
Update: The HEDUAfrica website has become part of the social media community with 75 Facebook likes (https://www.facebook.com/HeduAfrica) and 33 followers on Twitter (https://twitter.com/HEDUAfrica ) at present.
We have developed a multi-media resource that we envision will become a widely available tool for preventing and managing the causes and consequences of cardiovascular diseases in pregnancy and postpartum in Africa. We propose to distribute this resource widely to healthcare providers who manage pregnant women.
This project was initiated by Prof Karen Sliwa, together with the collective expertise of Prof John Anthony (Department of Obstetrics and Gynaecology, Groote Schuur Hospital), Dr Friedrich Thienemann (IIDMM, University of Cape Town) and Christian Diederichs (Integerafrica). It is supported by Prof D Levitt (NHLBI-funded NCD Centre of Excellence at the University of Cape Town) and Dr Vash Mungal-Singh (Heart and Stroke Foundation) and others.
This project received funding from the Medtronic Foundation USA (2011-2013)
Prof. Karen Sliwa, Hatter Institute
Prof. Simon Stewart: Baker IDI Heart and Diabetes Institute, Australia
Prof. John Anthony: Obstetrics and Gynaecology, Groote Schuur Hospital, South Africa
Dr. Kim Lamont, NIH Millennium Leadership Programme Chronic Diseases, University of the Witwatersrand, South Africa
Prof. Kerstin Klipstein-Grobusch: NIH Millennium Chronic Diseases Leadership Programme Director, University of the Witwatersrand, South Africa
Prof. Elena Libhaber: Soweto Cardiovascular Research Unit, University of the Witwatersrand, South Africa
Prof. Shane Norris: MRC Mineral Metabolism Research Unit, Department of Paediatrics, University of the Witwatersrand, South Africa
Dr. Friedrich Thienemann: IIDMM, University of Cape Town
Miss Zulfah Albertyn (PhD student) & Mrs Sandra Pretorius (PhD student)
Educational levels in young African women remain at historical lows. This provides a particular challenge when attempting to optimise the health of mothers and babies through educational strategies. It is estimated that up to one in two pregnant women in urban communities like Soweto are either overweight or obese. In response, our group has pilot data showing the utility of an innovative information technology (IT)-based program to provide readily accessible and understandable health education to this vulnerable population (HEDUAfrica – www.hedu-africa.org).
The PROTECT-AFRICA Study is a multi-centre, appropriately powered, randomised control trial of an integrated, information technology-based educational Intervention programme, to minimise the risk of excessive weight gain in overweight (but not obese) pregnant African women versus an enhanced form of usual care. The study will involve 480 participants from two primary care clinics in Soweto and Cape Town. The study will conform to CONSORT guidelines for pragmatic trials (Zwarenstein, 2008 ). The primary endpoint will be the proportion of participants who gain > 12kg from 16 weeks to delivery. Key secondary endpoints for the mother is a change in BMI index, change in health knowledge, change in food choices, plasma micronutrient levels (vitamin C and folic acid), body composition, body perception, change in systolic and diastolic BP, and number of caesarean births, treatment for infection post-delivery, the occurrence of obstetric haemorrhages and the effect of health coaching via SMS technology (the SMS content will be based on the content from the video’s on the HeduAfrica site) Furthermore, the study endpoints for the newborn include, size of infant (weight), Apgar score, blood pressure and plasma vitamin C levels.
A prospective health-economics design analysis will examine the potential cost-benefits of the intervention to significantly reduce the proportion of pregnant women experiencing excessive weight gain (with associated adverse health outcomes) from a health service payer perspective. Data will also be extrapolated to a whole-of-community and health system-wide perspective.
If proven successful and associated with cost-benefits, the PROTECT-AFRICA intervention will provide an important opportunity to limit excessive weight gain in pregnant women in a low-income setting.